Table 2. Comparison of characteristics stratified according to age.
| Characteristics | < 65 yr (n = 213 [31.6]) | 65–75 yr (n = 316 [46.8]) | > 75 yr (n = 146 [21.6]) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2006–2010 | 2011–2015 | P | 2006–2010 | 2011–2015 | P | 2006–2010 | 2011–2015 | P | ||
| No. of patients | 77 (36.2) | 136 (63.8) | 105 (33.2) | 211 (66.8) | 42 (28.8) | 104 (71.2) | ||||
| Age, yr | 59.6 (55.8–61.6) | 60.2 (57.5–62.6) | 0.498 | 69.2 (66.9–72.0) | 69.9 (67.3–72.1) | 0.806 | 79.9 (76.8–82.7) | 77.7 (75.8–80.8) | 0.382 | |
| PSA, ng/mL | 6.32 (4.50–12.39) | 7.87 (5.61–17.22) | 0.380 | 8.75 (5.73–26.91) | 8.71 (5.63–24.47) | 0.366 | 32.09 (12.95–148.93) | 11.59 (6.49–33.66) | 0.481 | |
| Gleason score | 0.083 | 0.001 | 0.180 | |||||||
| 6–7 | 59 (76.6) | 84 (61.7) | 69 (65.7) | 124 (58.7) | 16 (38.1) | 46 (44.2) | ||||
| 8 | 11 (14.3) | 30 (22.1) | 15 (14.3) | 66 (31.3) | 11 (26.2) | 36 (34.6) | ||||
| 9–10 | 7 (9.1) | 22 (16.2) | 21 (20.0) | 21 (10.0) | 15 (35.7) | 22 (21.2) | ||||
| NCCN risk stratification | 0.423 | 0.001 | 0.016 | |||||||
| Very low | 2 (2.6) | 7 (5.1) | 1 (1.0) | 9 (4.3) | 1 (2.4) | 0 (0.0) | ||||
| Low | 7 (9.1) | 20 (14.7) | 4 (3.8) | 35 (16.6) | 1 (2.4) | 10 (9.6) | ||||
| Intermediate | 33 (42.9) | 44 (32.4) | 45 (42.9) | 51 (24.2) | 5 (11.9) | 24 (23.1) | ||||
| High | 14 (18.2) | 30 (22.1) | 17 (16.2) | 45 (21.3) | 5 (11.9) | 21 (20.2) | ||||
| Very high | 8 (10.4) | 13 (9.6) | 19 (18.1) | 39 (18.5) | 10 (23.8) | 21 (20.2) | ||||
| Regional | 8 (10.4) | 8 (5.9) | 3 (2.9) | 10 (4.7) | 1 (2.4) | 7 (6.7) | ||||
| Metastatic | 5 (6.5) | 14 (10.3) | 16 (15.2) | 22 (10.4) | 19 (45.2) | 21 (20.2) | ||||
| SEER summary stage | 0.296 | 0.295 | 0.007 | |||||||
| Localized | 49 (63.6) | 93 (68.4) | 64 (61.0) | 125 (59.2) | 13 (31.0) | 54 (51.9) | ||||
| Regional | 23 (29.9) | 29 (21.3) | 25 (23.8) | 64 (30.3) | 10 (23.8) | 29 (27.9) | ||||
| Distant | 5 (6.5) | 14 (10.3) | 14 (10.3) | 22 (10.4) | 19 (45.2) | 21 (20.2) | ||||
| CAPRA scores | 59 (76.6) | 106 (77.9) | 0.032 | 75 (71.4) | 148 (70.1) | 0.157 | 18 (42.9) | 66 (65.4) | 0.959 | |
| 0–2 | 32 (54.2) | 37 (34.9) | 20 (26.7) | 54 (36.5) | 3 (16.7) | 13 (19.1) | ||||
| 3–5 | 16 (27.1) | 49 (46.2) | 36 (48.0) | 52 (35.1) | 7 (38.9) | 27 (39.7) | ||||
| 6–10 | 11 (18.6) | 20 (18.9) | 19 (25.3) | 42 (28.4) | 8 (44.4) | 28 (41.2) | ||||
| Initial treatment | 0.253 | 0.050 | 0.075 | |||||||
| AS | 0 (0.0) | 2 (1.5) | 1 (1.0) | 5 (2.4) | 1 (2.4) | 0 (0.0) | ||||
| RP | 55 (71.4) | 80 (58.8) | 56 (53.3) | 82 (38.9) | 3 (7.1) | 9 (8.7) | ||||
| RT + ADT | 14 (18.2) | 35 (25.7) | 30 (28.6) | 90 (42.7) | 20 (47.6) | 68 (65.4) | ||||
| ADT | 8 (10.4) | 19 (14.0) | 18 (17.1) | 34 (16.1) | 18 (42.9) | 27 (26.0) | ||||
Data are presented as number (%) or median (interquartile range).
PSA = prostate-specific antigen, NCCN = National Comprehensive Cancer Network, SEER = Surveillance, Epidemiology, and End Results, CAPRA = Cancer of the Prostate Risk Assessment, AS = active surveillance, RP = radical prostatectomy, RT = radiotherapy, ADT = androgen deprivation therapy.